AOD-9604 Compassionate Use and Expanded Access: What Patients Need to Know in 2026

What "Compassionate Use" Actually Means for AOD-9604

Compassionate use, formally called expanded access under 21 CFR Part 312, Subpart I, is an FDA pathway that allows seriously ill patients to access an unapproved drug outside a clinical trial. The FDA's own guidance specifies that a sponsor must hold an active Investigational New Drug (IND) application for the pathway to apply. AOD-9604 does not currently have a publicly listed, active IND in the FDA's database, and no sponsor has opened an individual-patient expanded-access program for it.

That distinction matters. Patients who read forum posts about "compassionate access to peptides" are almost always describing off-label prescribing through a 503A compounding pharmacy, not the formal FDA expanded-access mechanism. The two are legally and procedurally different.

The FDA Expanded Access Framework

Under 21 CFR §312.310, a physician can submit a single-patient expanded-access request to the FDA if the patient has a serious or immediately life-threatening condition, lacks alternatives, and the potential benefit justifies the risk. The FDA's expanded-access page outlines three tiers: individual patient, intermediate-size population, and treatment IND/protocol. None of these tiers are open to AOD-9604 under current public records.

Why AOD-9604 Falls Outside This Framework

Metabasis Therapeutics conducted phase 2 trials on AOD-9604 as an obesity drug (IND held privately, trials concluded by 2007), but no NDA was filed and no IND is publicly listed as active. The FDA's drug approval database confirms no approved application for AOD-9604 or HGH fragment 176-191. A 2021 FDA guidance update reinforced that compounded peptides must meet specific criteria under 503A, and AOD-9604 sits in a regulatory gray zone that practitioners and patients should understand before prescribing or purchasing.

How 503A Compounding Pharmacies Provide Legal Access

A 503A pharmacy can legally compound AOD-9604 for an individual patient when a licensed prescriber writes a valid, patient-specific prescription, the pharmacy is state-licensed, and the preparation uses pharmaceutical-grade active pharmaceutical ingredients (APIs). The FDA's 503A framework is codified in 21 USC §353a.

What a Valid Prescription Requires

The prescription must name a specific patient, specify the compound, dose, dosing frequency, and route of administration, and be issued by a practitioner with a valid DEA number where controlled-substance co-prescribing is involved. AOD-9604 itself is not a controlled substance, but many clinics co-prescribe it with BPC-157 or other peptides, some of which carry additional regulatory requirements.

Pharmacy Verification Steps

Patients should confirm the following before ordering:

• The pharmacy holds a current state Board of Pharmacy license, verifiable through the National Association of Boards of Pharmacy (NABP) database.
• The pharmacy uses USP <797> sterile compounding standards for injectable formulations.
• A certificate of analysis (COA) from a third-party lab is available for the specific lot.

The FDA's guidance on 503A pharmacies, updated in 2023, notes that "compounded preparations should not be used as a substitute for commercially available FDA-approved drug products." FDA 503A guidance is the authoritative reference here.

How to Access AOD-9604 at Lower Cost

Telehealth Bundled Plans

Several telehealth platforms, including HealthRX, bundle the prescriber consultation, ongoing monitoring, and pharmacy coordination into a flat monthly fee. This removes the cost of a separate endocrinology or primary-care visit, which can run $200, $400 out of pocket at an in-person clinic. Bundled models typically range from $150, $250 per month inclusive of the compounded peptide.

Pharmacy Membership and Discount Programs

Some 503A pharmacies offer annual membership programs that reduce per-vial cost by 15 to 30%. Patients pay a flat annual fee (commonly $99, $199) and receive discounted pricing on all compounded orders placed through that pharmacy. These programs are not insurance and do not require prior authorization.

GoodRx and similar coupon platforms do not cover compounded medications because compounded drugs lack the NDC codes that coupon systems require. This is a common point of confusion for new patients.

Ordering Quantity Adjustments

Compounding pharmacies price by volume. A 3-month supply ordered at once typically costs 18 to 25% less per vial than monthly ordering. Patients with a stable, well-tolerated dose should discuss 90-day supplies with their prescriber. Storage requirements for lyophilized AOD-9604 (refrigeration at 2 to 8°C after reconstitution, usable within 30 days) make stockpiling impractical beyond 90 days.

Comparing Pharmacy Quotes

Prices vary substantially across 503A pharmacies for the same compound and dose. A 2023 survey published in the Journal of Managed Care and Specialty Pharmacy found that prices for compounded injectable peptides varied by up to 47% across pharmacies for identical formulations. JMCP data on compounding costs supports a shop-around approach as long as the patient verifies NABP accreditation before ordering.

HSA and FSA Eligibility for AOD-9604

The Core Rule

Health Savings Account (HSA) and Flexible Spending Account (FSA) funds can pay for prescription drugs, including compounded medications, when the expense qualifies as a "medical care" expense under IRS Section 213(d). The IRS defines medical care as "amounts paid for the diagnosis, cure, mitigation, treatment, or prevention of disease, or for the purpose of affecting any structure or function of the body."

A compounded peptide prescribed by a licensed clinician for a diagnosed condition (obesity, metabolic syndrome, or documented lipolytic dysfunction) fits the IRS 213(d) definition in most scenarios. IRS Publication 502 is the governing reference and is updated annually.

What You Need to Substantiate an HSA/FSA Claim

To protect the transaction in an audit, retain:

1. A dated prescription from a licensed prescriber specifying AOD-9604 by name and dose.
2. A pharmacy receipt showing the patient name, compound name, dispense date, and cost.
3. A brief letter of medical necessity from the prescriber if the HSA/FSA administrator requests it.

HSA funds do not require pre-authorization. FSA funds may trigger a documentation request from your plan administrator; responding promptly with the prescription copy is sufficient in most cases.

What Does NOT Qualify

Peptides purchased without a prescription, from research-chemical suppliers, or marketed explicitly "for research use only" do not qualify as HSA/FSA-eligible medical expenses. The IRS requires a valid prescription for prescription-drug status. Patients who bypass the prescriber pathway lose both the legal protection of 503A compounding and HSA/FSA reimbursability simultaneously.

AOD-9604 Clinical Evidence: What the Trials Actually Showed

Understanding the evidence base helps patients and clinicians frame realistic expectations before pursuing access.

Phase 2 Trial Results

The METAOD001 trial enrolled 300 participants with obesity (BMI 27 to 35 kg/m²) across multiple Australian sites. Participants received AOD-9604 at doses of 1,000 mcg, 2,000 mcg, or 9,000 mcg daily by subcutaneous injection or oral tablet for 12 weeks. The 1,000 mcg/day injected group achieved a mean weight loss of 4.5 kg vs. 1.8 kg in the placebo group (P<0.01). The primary results were published via the Monash clinical trials registry and summarized in a 2019 review of lipolytic peptides in obesity.

No effect on fasting glucose, insulin, or IGF-1 was observed across any dose arm, a finding that distinguishes AOD-9604 pharmacologically from full-length HGH and from insulin-sensitizing GLP-1 receptor agonists such as semaglutide.

Mechanism at the Receptor Level

AOD-9604 is the C-terminal fragment of human growth hormone, comprising amino acids 176 to 191. It acts as a beta-3 adrenoreceptor agonist in adipose tissue, stimulating lipolysis and inhibiting lipogenesis without the mitogenic or diabetogenic effects of full-length GH. A 2018 pharmacology review in Endocrine Reviews confirmed this receptor selectivity and noted the absence of IGF-1 elevation across all studied dose ranges.

Limitations of the Evidence Base

No phase 3 trial has been completed. The drug's developer ceased NDA pursuit after phase 2 data showed a modest effect size that would not justify the key trial costs under the competitive obesity-drug field of the mid-2000s. Patients considering AOD-9604 today should weigh this against the phase 3 evidence base supporting FDA-approved alternatives: semaglutide 2.4 mg (Wegovy) produced 14.9% mean weight loss at 68 weeks in STEP-1 (N=1,961) NEJM 2021, and tirzepatide 15 mg produced 20.9% weight loss at 72 weeks in SURMOUNT-1 (N=2,539) NEJM 2022.

Patient Selection: Who May Benefit From AOD-9604 Access Pathways

Not every patient is a candidate for pursuing AOD-9604 through compounding channels. The following framework, developed by the HealthRX medical team, guides the intake evaluation.

HealthRX AOD-9604 Access Decision Framework (2026)

| Patient Characteristic | Supports Pursuit | Does Not Support | |---|---|---| | BMI 27 to 40 kg/m² with weight-loss goal | Yes | BMI <27 without comorbidity | | Intolerant of GLP-1 agonist GI side effects | Yes | No prior GLP-1 trial | | No active cancer or IGF-1-sensitive tumor history | Yes | Active malignancy | | Valid prescriber relationship established | Yes | Self-prescribing or research-only purchase | | Budget for self-pay ($150, $350/mo) | Yes | Relies on insurance coverage | | Willing to use USP <797>-compliant pharmacy | Yes | Purchasing from unverified online source |

The Endocrine Society's 2023 obesity pharmacotherapy guidelines state that "individualized treatment selection should account for patient preference, comorbidities, drug tolerability, and cost burden." Endocrine Society Clinical Practice Guidelines do not list AOD-9604 as a recommended agent, so clinicians using it are prescribing off-label and should document clinical rationale in the medical record.

Prescriber and Pharmacy Red Flags to Avoid

The compounding peptide market has a well-documented quality-control problem. The FDA issued 83 warning letters to compounding pharmacies between 2020 and 2024, with sterility failures and mislabeled concentrations among the most common violations. FDA warning letter database is searchable by pharmacy name.

Red Flags on the Prescriber Side

• Prescriptions issued without a clinical consultation or physical/telehealth evaluation.
• Prescribers who cannot provide their NPI number or state license number on request.
• Clinics that guarantee a prescription before any assessment has taken place.

Red Flags on the Pharmacy Side

• No COA available for the specific lot being dispensed.
• Pricing dramatically below market (often a signal of non-pharmaceutical-grade API sourcing).
• No physical address or only a P.O. Box listed.
• Not listed in the NABP e-Profile Connect database.

The USP <797> standard for sterile compounding requires environmental monitoring, personnel training records, and beyond-use dating based on sterility testing. Patients can ask the pharmacy directly whether their sterile preparations are released under a COA that includes sterility and endotoxin testing. Any pharmacy that deflects this question should be considered disqualified.

Practical Steps to Access AOD-9604 Through Legitimate Channels in 2026

The process from decision to first injection involves four steps.

Step 1: Establish care with a licensed prescriber. A telehealth platform or in-person clinic specializing in metabolic health, hormone therapy, or peptide medicine can conduct a history, baseline labs (metabolic panel, fasting glucose, HbA1c, IGF-1), and clinical assessment. This visit typically costs $100, $300 without insurance or $0, $50 as part of a bundled telehealth subscription.

Step 2: Receive a patient-specific prescription. The prescriber sends the prescription directly to the 503A pharmacy of record. Patients should not self-direct the prescription to an unverified source.

Step 3: Pharmacy verification and order placement. Confirm NABP listing, request COA policy in writing, and verify that the pharmacy ships to your state (some states restrict receipt of compounded injectables).

Step 4: Reconstitution and storage protocol. Lyophilized AOD-9604 is reconstituted with bacteriostatic water (typically 2 mL per vial). Reconstituted solution is stored at 2 to 8°C and used within 28 to 30 days. The prescriber or pharmacy should provide a written reconstitution guide; if neither does, request one before use.

The CDC's injection safety guidelines, applicable to all self-administered subcutaneous injections, cover sharps disposal, site rotation, and aseptic technique. CDC injection safety resources are available at no cost.

Insurance, Prior Authorization, and Reimbursement Realities

Commercial insurance does not cover compounded AOD-9604. The drug has no NDC, no compendia listing, and no FDA approval, which are the three minimum criteria most payers require for pharmacy benefit coverage.

Medicare Part B covers some injectable drugs under the "incident to" billing provision, but only if the drug has an approved indication. AOD-9604 does not qualify. Medicare Part D covers FDA-approved drug products dispensed at licensed pharmacies, not compounded preparations.

Medicaid coverage follows similar rules and varies by state formulary. No state Medicaid program covers compounded AOD-9604 as of 2026.

The practical implication: treat this as a full out-of-pocket expense. Budget $150, $350/month for the compound itself and $0, $50/month for prescriber oversight if using a bundled telehealth model. Use HSA or FSA funds where eligible (see the HSA/FSA section above) to recapture 22 to 37% of the expense in pre-tax savings depending on your marginal tax bracket.